Article
Apr 3, 2026
Medical Referral Program: how clinical patient referrals work
Understand how clinical referral works in the medical referral program and how to safely refer patients for research.
Clinical indication is one of the most relevant acts in medical practice: it is a decision grounded in evidence, professional experience, and individualized patient assessment.
When it involves the possibility of participating in structured scientific studies, it is placed in an even more rigorous context — that of the medical referral program, an organized model that connects treating physicians to centers of excellence in clinical research.
The advancement of modern medicine is intrinsically linked to clinical research. According to the National Institutes of Health (NIH), clinical studies are of great importance for validating the safety, accuracy, and therapeutic impact of new interventions.
In today’s article, you will understand what Synvia’s Medical Referral Program is and how it works, how this relationship benefits the patient, the main responsibilities of the partner physician, and other topics. Shall we begin? Enjoy the reading!
What is the Medical Referral Program?
The medical referral program is a formalized structure that enables the treating physician to make a clinical indication of patients for evaluation in clinical research conducted by specialized centers.
We can define this program as a collaborative model that fully respects the principles of evidence-based medical practice and international ethical standards.
Unlike a simple referral, indication for research within a structured program occurs based on technical criteria defined in a protocol previously approved by Research Ethics Committees and, when applicable, by international regulatory agencies.
In practice, the medical referral program works as a scientific bridge between the medical office and the research center.
Clinical indication is made based on diagnosis, therapeutic history, and analysis of potential eligibility. From that point on, the research team conducts technical screening, keeping the treating physician informed as authorized by the patient.
➔ Do you want to refer your patients to safe clinical studies approved by ANVISA? Tap here and find out how to do it!
How does clinically indicating patients for research benefit the doctor-patient relationship?
Clinical indication for participation in research can deeply strengthen the therapeutic relationship when conducted with transparency, clarity, and scientific grounding.
The World Medical Association, through the Declaration of Helsinki, reinforces that the physician must always act in the patient’s best interest, including when proposing participation in scientific studies.
Among the most relevant benefits are:
Expansion of therapeutic alternatives: allows access to innovative therapies under development, especially in conditions with limited response to conventional treatments.
Rigorous clinical monitoring: clinical study protocols include systematic assessments, regular tests, and structured follow-up.
Shared and informed decision-making: the patient receives detailed explanations about risks, benefits, and alternatives.
Integration between care and science: the physician maintains parallel clinical follow-up.
Contribution to the advancement of medicine: participation strengthens future scientific evidence.
It is important to emphasize that clinical indication does not represent a transfer of care responsibility. The therapeutic bond remains preserved, while the research center assumes conduct of the experimental protocol.
What are the main responsibilities of the partner physician in Synvia studies?
The primary responsibility of the treating physician is to assess whether the clinical indication for participation in research is consistent with the patient’s profile, considering disease stage, therapeutic history, and available alternatives.
After indication for research, responsibility shifts to the study’s principal investigator, as provided for in Good Clinical Practices (ICH-GCP). However, the partner physician remains responsible for the patient’s overall care, including management of comorbidities unrelated to the study.
This collaboration requires structured communication, respect for confidentiality, and strong technical alignment among the parties involved.
How does report sharing work during the clinical study of referred patients?
Information sharing occurs upon the patient’s express authorization in the Informed Consent Form (ICF).
These reports may include information on visit schedules, monitored adverse events, and tests planned in the protocol.
Sharing respects principles of confidentiality and data protection, in accordance with international clinical research guidelines.
This transparency strengthens continuity of care, ensuring that clinical indication remains well integrated with clinical follow-up.
➔ Synvia is the largest clinical research company in Latin America, with more than 2,000 studies conducted and 30,000 participants. Tap here, become a treating physician, and be part of this story!
What are the safety and regulatory guarantees of clinical studies?
Clinical studies are evaluated by independent Ethics Committees, which analyze risk-benefit, methodology, and safeguards for participants.
ICH Good Clinical Practices establish international standards for the conduct, monitoring, and auditing of clinical studies. These standards include data traceability, continuous monitoring, and risk management.
In Brazil, the conduct of clinical research is regulated by Law No. 14,874/24, which establishes updated guidelines for carrying out studies involving human beings, including research with medicines under development.
This framework ensures that clinical indication within the Medical Referral Program takes place in an ethical, safe, and properly regulated environment.
What are the main benefits for the patient?
Participation in a clinical study may offer different benefits to the patient. These include structured follow-up by a specialized team, performance of tests and assessments planned in the protocol, and continuous monitoring of the health condition during the study.
Clinical studies also provide access to innovative therapies under development, especially in situations where response to conventional treatments is limited or unsatisfactory.
Participation is always voluntary and occurs through free and informed consent. There is no payment for the treatment itself, and there may only be reimbursement of study-related expenses, as provided in the protocol.
Screening process, eligibility criteria, and active programs at Synvia
After clinical indication within the medical referral program, screening begins. This stage verifies whether the patient meets inclusion criteria and does not present exclusion criteria defined in the protocol.
Criteria are established based on statistical and scientific foundations, aiming at safety and methodological validity.
Screening may include review of medical history, specific laboratory tests, and structured clinical interviews.
Eligibility criteria in Synvia clinical indication
Within the medical referral program, responsible clinical indication previously considers factors such as minimum or maximum age, diagnosis confirmed by internationally recognized criteria, stage of disease, prior therapeutic history, and presence of relevant comorbidities.
Each protocol has inclusion and exclusion criteria defined in the methodological design approved by independent Ethics Committees and ANVISA. These criteria are based on statistical and scientific foundations, ensuring participants have a profile compatible with the study objectives.
Proper clinical indication anticipates this analysis, allowing the partner physician to preliminarily assess whether the patient may or may not benefit from formal screening.
However, eligibility confirmation occurs only after a complete technical assessment carried out by the Synvia team, which provides detailed guidance on criteria and conducts all necessary clinical analysis.
It is essential to reinforce that the treating physician fully maintains patient follow-up. All prescriptions and therapeutic decisions remain under their responsibility, ensuring continuity of care even when the patient participates in clinical research within the program.
______________________________________________________________________________
Content continues after the video. Watch to learn more about the
Synvia Medical Referral Program. ↓
Or, if you prefer, access this page and sign up to refer patients.
______________________________________________________________________________
Which medical specialties currently have active studies at Synvia?
Synvia’s medical referral program includes clinical trials across multiple therapeutic areas, always under strict regulatory standards.
Frequently included specialties include endocrinology, immunology, infectious diseases, rheumatology, and rare conditions, as well as other areas depending on the opening of new protocols.
Protocol availability varies according to sponsors, research phases, and regulatory approvals.
Physicians interested in making referrals for research can consult the Synvia team to check active studies and understand which criteria are currently being applied.
➔ Tap here to better understand the subject and join Synvia’s Medical Referral Program.
What happens if the patient is not approved?
Not all patients submitted to screening will meet the eligibility criteria of a given protocol.
If this occurs, the patient remains under routine clinical follow-up with their treating physician, with no therapeutic harm or negative impact on their care relationship.
Not being included in a study does not mean a lack of alternatives. New protocols are continuously approved, enabling future clinical indications when there is compatibility with other criteria.
How does the referral form work for partner physicians?
This is the time to join Synvia’s medical referral program. The process is objective, ethical, and technically structured to facilitate your routine, without unnecessary bureaucracy and without compromising your clinical autonomy.
All data in our form are recorded with confidentiality, traceability, and regulatory compliance.
The referral does not imply automatic inclusion, but it starts specialized screening conducted by an experienced clinical research team.
By participating in the medical referral program, you expand your therapeutic arsenal at no additional cost to the patient, offering access to specialized tests and innovative treatments under evaluation.
Tap the button below and become part of Synvia’s Medical Referral Program.
_______________________________________________________________________________
REFERENCES
BRAZIL. National Health Council. Resolution No. 466, of December 12, 2012. Guidelines and regulatory standards for research involving human beings. Brasília, DF: National Health Council, 2012. Available at: https://conselho.saude.gov.br/resolucoes/2012/Reso466.pdf
INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE (ICH). Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). Geneva: ICH, 2016. Available at: https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf
WORLD MEDICAL ASSOCIATION. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Ferney-Voltaire: WMA, 2013 (later updates). Available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
NATIONAL INSTITUTES OF HEALTH (NIH). Clinical Research and Clinical Trials Information for Patients and Professionals. Bethesda: NIH, n.d. Available at: https://clinicaltrials.gov/ct2/about-studies/learn
U.S. FOOD AND DRUG ADMINISTRATION (FDA). Clinical Trials: What Patients Need to Know. Silver Spring: FDA, n.d. Available at: https://www.fda.gov/patients/learn-about-clinical-trials/clinical-trials-what-patients-need-know
NATIONAL HEALTH SURVEILLANCE AGENCY (ANVISA). Clinical research with medicines in Brazil: standards and regulation. Brasília: ANVISA, n.d. Available at: https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/pesquisa-clinica